Literature DB >> 18976853

Bioactivation of the phytoestrogen diosmetin by CYP1 cytochromes P450.

Vasilis Androutsopoulos1, Nicola Wilsher, Randolph R J Arroo, Gerry A Potter.   

Abstract

Breast cancer is a major cause of death worldwide. Amongst the various forms of treatment chemoprevention is favoured and natural products such as the dietary flavonoids have been examined for their cancer preventative activity. In this study we investigated the anticancer activity of the flavonoid diosmetin, as a result of cytochrome P450 CYP1 metabolism. Diosmetin was metabolized to luteolin via an aromatic demethylation reaction on the B-ring from CYP1A1, CYP1B1 and the hepatic isozyme CYP1A2. CYP1A1 and CYP1A2 also produced additional unidentified metabolites. CYP1B1 showed the lowest apparent KM and CYP1A1 the highest apparent Kcat. Diosmetin was also metabolized to luteolin in estrogen receptor positive breast cell-line (MCF-7 cells) preinduced for 24 h with the potent CYP1 inducer 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Treatment of MCF-7 cells with TCDD caused bioactivation of diosmetin enhancing its cytotoxicity. Taken together these data suggest that the flavonoid diosmetin is metabolised to the more active molecule luteolin by CYP1 family enzymes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18976853     DOI: 10.1016/j.canlet.2008.08.032

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  11 in total

Review 1.  A review on pharmacological and analytical aspects of diosmetin: a concise report.

Authors:  Kanika Patel; Manoj Gadewar; Vijay Tahilyani; Dinesh Kumar Patel
Journal:  Chin J Integr Med       Date:  2013-10-04       Impact factor: 1.978

2.  Preference for O-demethylation reactions in the oxidation of 2'-, 3'-, and 4'-methoxyflavones by human cytochrome P450 enzymes.

Authors:  Haruna Nagayoshi; Norie Murayama; Masaki Tsujino; Shigeo Takenaka; Jun Katahira; Vitchan Kim; Donghak Kim; Masayuki Komori; Hiroshi Yamazaki; F Peter Guengerich; Tsutomu Shimada
Journal:  Xenobiotica       Date:  2020-04-30       Impact factor: 1.908

Review 3.  Pharmacology of Diosmin, a Citrus Flavone Glycoside: An Updated Review.

Authors:  Samar H Gerges; Sara A Wahdan; Doaa A Elsherbiny; Ebtehal El-Demerdash
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-10-23       Impact factor: 2.441

4.  EPA Modulates KLK Genes via miR-378: A Potential Therapy in Prostate Cancer.

Authors:  Kai-Jie Yu; De-Yi Ji; Ming-Li Hsieh; Cheng-Keng Chuang; See-Tong Pang; Wen-Hui Weng
Journal:  Cancers (Basel)       Date:  2022-06-06       Impact factor: 6.575

5.  Diosmetin induces apoptosis by upregulating p53 via the TGF-β signal pathway in HepG2 hepatoma cells.

Authors:  Bin Liu; Yufeng Shi; Wending Peng; Qingyu Zhang; Jie Liu; Nianping Chen; Runzhi Zhu
Journal:  Mol Med Rep       Date:  2016-05-12       Impact factor: 2.952

6.  Radiosensitizing effect of diosmetin on radioresistant lung cancer cells via Akt signaling pathway.

Authors:  Zhijie Xu; Yuanliang Yan; Lingfang Xiao; Shuang Dai; Shuangshuang Zeng; Long Qian; Lin Wang; Xue Yang; Yi Xiao; Zhicheng Gong
Journal:  PLoS One       Date:  2017-04-17       Impact factor: 3.240

7.  Pharmacokinetic study of luteolin, apigenin, chrysoeriol and diosmetin after oral administration of Flos Chrysanthemi extract in rats.

Authors:  Zhongjian Chen; Sisi Kong; Feifeng Song; Liping Li; Huidi Jiang
Journal:  Fitoterapia       Date:  2012-09-20       Impact factor: 2.882

Review 8.  Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention.

Authors:  Vasilis P Androutsopoulos; Aristidis M Tsatsakis; Demetrios A Spandidos
Journal:  BMC Cancer       Date:  2009-06-16       Impact factor: 4.430

9.  Identification of small molecule activators of BMP signaling.

Authors:  Karen Vrijens; Wenwei Lin; Jimmy Cui; Dana Farmer; Jonathan Low; Elodie Pronier; Fu-Yue Zeng; Anang A Shelat; Kiplin Guy; Michael R Taylor; Taosheng Chen; Martine F Roussel
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

10.  Diosmetin suppresses human prostate cancer cell proliferation through the induction of apoptosis and cell cycle arrest.

Authors:  Christine Oak; Ahmad O Khalifa; Ilaha Isali; Natarajan Bhaskaran; Ethan Walker; Sanjeev Shukla
Journal:  Int J Oncol       Date:  2018-05-16       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.